These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18000579)

  • 21. Clinical manifestations of acetylcholine receptor antibody positive and negative myasthenia gravis.
    Pasutharnchat N; Wacharapluesadee S; Hemachudha T
    J Med Assoc Thai; 2012 Mar; 95(3):313-9. PubMed ID: 22550827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis.
    Zhang B; Tzartos JS; Belimezi M; Ragheb S; Bealmear B; Lewis RA; Xiong WC; Lisak RP; Tzartos SJ; Mei L
    Arch Neurol; 2012 Apr; 69(4):445-51. PubMed ID: 22158716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acetylcholine receptor antibody in Thai generalized myasthenia gravis patients.
    Jitpimolmard S; Taimkao S; Chotmongkol V; Sawanyawisuth K; Vincent A; Newsom-Davis J
    J Med Assoc Thai; 2006 Jan; 89(1):68-71. PubMed ID: 16583584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
    Hoch W; McConville J; Helms S; Newsom-Davis J; Melms A; Vincent A
    Nat Med; 2001 Mar; 7(3):365-8. PubMed ID: 11231638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-AChR-negative myasthenia gravis: clinical and immunological features.
    Evoli A; Bartoccioni E; Batocchi AP; Scuderi F; Tonali P
    Clin Invest Med; 1989 Apr; 12(2):104-9. PubMed ID: 2706833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mortality in myasthenia gravis: A nationwide population-based follow-up study in Denmark.
    Hansen JS; Danielsen DH; Somnier FE; Frøslev T; Jakobsen J; Johnsen SP; Andersen H
    Muscle Nerve; 2016 Jan; 53(1):73-7. PubMed ID: 25914186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors Affecting Generalization of Ocular Myasthenia Gravis in Patients With Positive Acetylcholine Receptor Antibody.
    Apinyawasisuk S; Chongpison Y; Thitisaksakul C; Jariyakosol S
    Am J Ophthalmol; 2020 Jan; 209():10-17. PubMed ID: 31562855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical correlation of anti-receptor antibody titer, sensitivity to curare and electromyographic changes in experimental autoimmune myasthenia gravis].
    Chen SM
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1990 Oct; 23(5):293-6, 320. PubMed ID: 2282884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pseudo-internuclear ophthalmoplegia in myasthenia gravis].
    Bogdan I; Crisanda V
    Oftalmologia; 2011; 55(3):70-3. PubMed ID: 22428294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of sera from seronegative myasthenia gravis patients on neuromuscular junctions.
    Sato R; Imamoto S; Utsnomiya I; Chiba T; Taguchi K; Abe K; Tanaka K; Miyatake T
    Neurol Sci; 2013 Oct; 34(10):1735-44. PubMed ID: 23389808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-alkaline phosphatase antibody positive myasthenia gravis.
    Konishi T; Ohta K; Shigemoto K; Ohta M
    J Neurol Sci; 2007 Dec; 263(1-2):89-93. PubMed ID: 17628604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Seronegative myasthenia gravis.
    Vincent A; McConville J; Farrugia ME; Newsom-Davis J
    Semin Neurol; 2004 Mar; 24(1):125-33. PubMed ID: 15229799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?
    Sanders DB; Burns TM; Cutter GR; Massey JM; Juel VC; Hobson-Webb L;
    Muscle Nerve; 2014 Apr; 49(4):483-6. PubMed ID: 23835683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Change in myasthenia gravis epidemiology in Trento, Italy, after twenty years.
    Pallaver F; Riviera AP; Piffer S; Ricciardi R; Roni R; Orrico D; Bonifati DM
    Neuroepidemiology; 2011; 36(4):282-7. PubMed ID: 21757957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Juvenile myasthenia gravis in Norway: A nationwide epidemiological study.
    Popperud TH; Boldingh MI; Brunborg C; Faiz KW; Heldal AT; Maniaol AH; Müller KI; Rasmussen M; Øymar K; Kerty E
    Eur J Paediatr Neurol; 2017 Mar; 21(2):312-317. PubMed ID: 27666466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Autoantibodies in myasthenia gravis].
    Motomura M; Narita Masuda T
    Brain Nerve; 2013 Apr; 65(4):433-9. PubMed ID: 23568991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of myasthenia gravis in the province of Ferrara: a community-based study.
    Casetta I; Fallica E; Govoni V; Azzini C; Tola M; Granieri E
    Neuroepidemiology; 2004; 23(6):281-4. PubMed ID: 15297794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Matrix metalloproteinases in myasthenia gravis.
    Helgeland G; Petzold A; Luckman SP; Gilhus NE; Plant GT; Romi FR
    Eur Neurol; 2011; 65(1):53-8. PubMed ID: 21212676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
    Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
    Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.